Skip to content

Operating Income at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.8M-131%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$19.46M-6.8%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
-$119.41M-25.9%
Exelixis logo
ExelixisEXEL
$251.34M+34.5%

Other financials

Income statement

See full
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s operating income?
Nuvectis Pharma, Inc. (NVCT) reported operating income of -$6.26M in Q1 2026.
How has Nuvectis Pharma, Inc.'s operating income changed year-over-year?
Nuvectis Pharma, Inc.'s operating income decreased by 12.4% year-over-year, from -$5.57M to -$6.26M.
What is the long-term trend for Nuvectis Pharma, Inc.'s operating income?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s operating income has grown at a 20.9% compound annual growth rate (CAGR), from -$12.89M to -$27.57M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.